{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-100117","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2021-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.281695+00:00","generated_at":"2026-06-29T22:58:57.029358+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Armata Pharmaceuticals appoints Brian Varnum as CEO; Todd Patrick resigns but stays as advisor","bullets":["Brian Varnum, Ph.D. appointed CEO effective August 1, 2021; was previously President and Chief Development Officer.","Todd R. Patrick resigned as CEO as of Aug 1, 2021; continues as board member until next annual meeting and as advisor through Dec 31, 2022.","Patrick to receive base salary of $550K through Dec 2021, then $275K through transition period; target bonus 50% of base.","Varnum receives base salary $500K, target bonus 50%, and option to purchase 125,000 shares vesting over 4 years.","Half of Patrick's unvested stock options and RSUs vest at end of transition period if he serves full term."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-100117","json":"https://secwatch.observer/filing/0001104659-21-100117.json","markdown":"https://secwatch.observer/filing/0001104659-21-100117.md","text":"https://secwatch.observer/filing/0001104659-21-100117.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465921100117/0001104659-21-100117-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465921100117/tm2124032d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:58:57.029358+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a47c42755a","claim":"Todd R. Patrick resigned as Chief Executive Officer at Armata Pharmaceuticals, Inc..","evidence_excerpt":"Todd R. Patrick, who has served as the Company’s CEO since May 2019, resigned as CEO as of August 1, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921100117/0001104659-21-100117-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"deac60dc6f","claim":"Brian Varnum was appointed as Chief Executive Officer at Armata Pharmaceuticals, Inc..","evidence_excerpt":"On August 1, 2021, Brian Varnum, Ph.D. was appointed to serve as Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465921100117/0001104659-21-100117-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}